Trial Profile
A First in Human Clinical Study on the Safety and Tolerability of Two Escalating Single Doses of CHF 5633 (Synthetic Surfactant) in Preterm Neonates With Respiratory Distress Syndrome
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Aug 2020
Price :
$35
*
At a glance
- Drugs Elifactant (Primary)
- Indications Neonatal respiratory distress syndrome
- Focus Adverse reactions; First in man
- Sponsors Chiesi Farmaceutici
- 01 Nov 2017 Results assessing safety and tolerability of CHF5633 and exploring preliminary efficacy published in the Archives of Disease in Childhood. Fetal and Neonatal Edition
- 08 Feb 2015 Status changed from recruiting to completed according to ClinicalTrials.gov record.
- 30 May 2014 New trial record